Specificity of the Immune Response to a Modified Group B Meningococcal Polysaccharide Conjugate Vaccine

Moore, Samuel L.; Farley, Esmé K.; Fusco, Peter C.; Michon, Francis

doi:10.1128/cvi.00216-06

Cited by 4 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Men B CPS is therefore perceived as self-antigen by the innate immune system and it induces immune tolerance. Structural modification of this “self” antigen replacing the N -acetyl group of sialic acid units with an N -propanonyl group [ 165 ] induced high levels of bactericidal IgG antibodies without detection of autoantibodies [ 166 ]. However, its development has been suspended due to the poor performance of the vaccine in a limited human trial and to the high perceived risk of autoimmunity [ 61 ].…”

Section: Neisseria Meningitidismentioning

confidence: 99%

Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development

2018

View full text Add to dashboard Cite

During the last decade there has been a growing interest in glycoimmunology, a relatively new research field dealing with the specific interactions of carbohydrates with the immune system. Pathogens’ cell surfaces are covered by a thick layer of oligo- and polysaccharides that are crucial virulence factors, as they mediate receptors binding on host cells for initial adhesion and organism invasion. Since in most cases these saccharide structures are uniquely exposed on the pathogen surface, they represent attractive targets for vaccine design. Polysaccharides isolated from cell walls of microorganisms and chemically conjugated to immunogenic proteins have been used as antigens for vaccine development for a range of infectious diseases. However, several challenges are associated with carbohydrate antigens purified from natural sources, such as their difficult characterization and heterogeneous composition. Consequently, glycoconjugates with chemically well-defined structures, that are able to confer highly reproducible biological properties and a better safety profile, are at the forefront of vaccine development. Following on from our previous review on the subject, in the present account we specifically focus on the most recent advances in the synthesis and preliminary immunological evaluation of next generation glycoconjugate vaccines designed to target bacterial and fungal infections that have been reported in the literature since 2011.

show abstract

Section: Neisseria Meningitidismentioning

confidence: 99%